Cargando…
Early viral protein synthesis is necessary for NF-κB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells
Modified vaccinia Ankara (MVA) is an attenuated vaccinia virus, and is a promising vaccine vector for variola and monkeypox viruses, as well as for other pathogens. The MVA determinants important for vaccine efficacy and immunogenicity are poorly defined. MVA infection of fibroblast cells activates...
Autores principales: | Martin, Stefani, Shisler, Joanna L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741392/ https://www.ncbi.nlm.nih.gov/pubmed/19539971 http://dx.doi.org/10.1016/j.virol.2009.05.014 |
Ejemplares similares
-
Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014) -
A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
por: Jordan, Ingo, et al.
Publicado: (2013) -
Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013) -
Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified Vaccinia virus Ankara (MVA)
por: Marcacci, Maurilia, et al.
Publicado: (2020) -
Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
por: Klaas, Lioba, et al.
Publicado: (2021)